argenx planning Phase III for thrombocytopenia therapy

argenx S.E. (Euronext:ARGX; NASDAQ:ARGX) said it plans to start Phase III testing of IV efgartigimod (ARGX-113) to treat primary immune thrombocytopenia (ITP) after reporting that the compound led to clinically meaningful platelet count improvements in a Phase II trial in the indication. Efgartigimod is a human antibody Fc fragment that targets neonatal Fc receptor (FCRN; FCGRT).

The company followed the Sept. 17 data announcement by raising $300.6 million on Sept. 19 through the sale of 3.5 million ADSs at $86.50 in a follow-on underwritten by Morgan Stanley, Cowen, Evercore ISI, Kempen and Nomura...